Positioning of inflammatory biomarkers in the heart failure landscape

Journal of Cardiovascular Translational Research

Volumn 6, Issue 4, 2013, Pages 485-492

  Hartupee, Justin ^a   Mann, Douglas L ^a  

^a WASHINGTON UNIVERSITY   (United States)

Author keywords

Biomarkers; C reactive protein (CRP); Cytokine receptors; Galectin 3; Heart failure; Inflammation; Interleukins; Pentraxin 3; Pro inflammatory cytokines; sST2; Tumor necrosis factor

Indexed keywords

BIOLOGICAL MARKER; CYTOKINE; CYTOKINE RECEPTOR; FAS LIGAND; GALECTIN 3; GLYCOPROTEIN GP 130; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; INTERLEUKIN 1 RECEPTOR LIKE 1; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 33; INTERLEUKIN 6; INTERLEUKIN 8; PENTRAXIN 3; PROTEIN TNFSF12; PROTEIN TNFSF2; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ACCURACY; ACUTE HEART FAILURE; ARTICLE; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; DISEASE SEVERITY; HEART EJECTION FRACTION; HEART FAILURE; HUMAN; INFLAMMATION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; SYMPTOM;

ANIMALS; BIOLOGICAL MARKERS; CYTOKINES; DISEASE PROGRESSION; HEART FAILURE; HUMANS; INFLAMMATION; INFLAMMATION MEDIATORS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS;

EID: 84880417197     PISSN: 19375387     EISSN: 19375395     Source Type: Journal    
DOI: 10.1007/s12265-013-9467-y     Document Type: Article

References (43)

1. Askevold, E. T.; Nymo, S.; Ueland, T.; Gravning, J.; Wergeland, R.; Kjekshus, J.; et al. (2013). Soluble glycoprotein 130 predicts fatal outcomes in chronic heart failure: Analysis from the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). Circulation Heart Failure, 6, 91-98.
2. Bozkurt, B.; Mann, D. L.; & Deswal, A. (2010). Biomarkers of inflammation in heart failure. Heart Failure Reviews, 15, 331-341.
3. Chin, B. S.; Conway, D. S.; Chung, N. A.; Blann, A. D.; Gibbs, C. R.; & Lip, G. Y. (2003). Interleukin-6, tissue factor and von Willebrand factor in acute decompensated heart failure: Relationship to treatment and prognosis. Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis, 14, 515-521.
4. Deswal, A.; Petersen, N. J.; Feldman, A. M.; Young, J. B.; White, B. G.; & Mann, D. L. (2001). Cytokines and cytokine receptors in advanced heart failure: An analysis of the cytokine database from the Vesnarinone Trial (VEST). Circulation, 103, 2055-2059.
5. Doroudgar, S.; & Glembotski, C. C. (2011). The cardiokine story unfolds: Ischemic stress-induced protein secretion in the heart. Trends in Molecular Medicine, 17, 207-214.
6. Dunlay, S. M.; Weston, S. A.; Redfield, M. M.; Killian, J. M.; & Roger, V. L. (2008). Tumor necrosis factor-alpha and mortality in heart failure: A community study. Circulation, 118, 625-631.
7. Gallucci, S.; & Matzinger, P. (2001). Danger signals: SOS to the immune system. Current Opinion in Immunology, 13, 114-119.
8. Gullestad, L.; Ueland, T.; Kjekshus, J.; Nymo, S. H.; Hulthe, J.; Muntendam, P.; et al. (2012). The predictive value of galectin-3 for mortality and cardiovascular events in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA). American Heart Journal, 164, 878-883.
9. Gullestad, L.; Ueland, T.; Vinge, L. E.; Finsen, A.; Yndestad, A.; & Aukrust, P. (2012). Inflammatory cytokines in heart failure: Mediators and markers. Cardiology, 122, 23-35.
10. Ionita, M. G.; Arslan, F.; de Kleijn, D. P.; & Pasterkamp, G. (2010). Endogenous inflammatory molecules engage Toll-like receptors in cardiovascular disease. Journal of Innate Immunity, 2, 307-315.
11. Jacobshagen, C.; Belardinelli, L.; Hasenfuss, G.; & Maier, L. S. (2011). Ranolazine for the treatment of heart failure with preserved ejection fraction: Background, aims, and design of the RALI-DHF study. Clinical Cardiology, 34, 426-432.
12. Januzzi, J. L.; Jr.; Peacock, W. F.; Maisel, A. S.; Chae, C. U.; Jesse, R. L.; Baggish, A. L.; et al. (2007). Measurement of the interleukin family member ST2 in patients with acute dyspnea: Results from the PRIDE (Pro-Brain Natriuretic Peptide Investigation of Dyspnea in the Emergency Department) study. Journal of the American College of Cardiology, 50, 607-613.
13. Kalogeropoulos, A.; Georgiopoulou, V.; Psaty, B. M.; Rodondi, N.; Smith, A. L.; Harrison, D. G.; et al. (2010). Inflammatory markers and incident heart failure risk in older adults: The Health ABC (Health, Aging, and Body Composition) study. Journal of the American College of Cardiology, 55, 2129-2137.
14. Ky, B.; French, B.; Levy, W. C.; Sweitzer, N. K.; Fang, J. C.; Wu, A. H.; et al. (2012). Multiple biomarkers for risk prediction in chronic heart failure. Circulation. Heart Failure, 5, 183-190.
15. Ky, B.; French, B.; McCloskey, K.; Rame, J. E.; McIntosh, E.; Shahi, P.; et al. (2011). High-sensitivity ST2 for prediction of adverse outcomes in chronic heart failure. Circulation. Heart Failure, 4, 180-187.
16. Latini, R.; Gullestad, L.; Masson, S.; Nymo, S. H.; Ueland, T.; Cuccovillo, I.; et al. (2012). Pentraxin-3 in chronic heart failure: The CORONA and GISSI-HF trials. European Journal of Heart Failure, 14, 992-999.
17. Levine, B.; Kalman, J.; Mayer, L.; Fillit, H. M.; & Packer, M. (1990). Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. The New England Journal of Medicine, 223, 236-241.
18. Levine, S. J. (2008). Molecular mechanisms of soluble cytokine receptor generation. The Journal of Biological Chemistry, 283, 14177-14181.
19. Luft, F. C. (2001). Angiotensin, inflammation, hypertension, and cardiovascular disease. Current Hypertension Reports, 3, 61-67.
20. Mann, D. L. (1996). Stress activated cytokines and the heart. Cytokine & Growth Factor Reviews, 7, 341-354.
21. Mann, D. L. (2002). Inflammatory mediators and the failing heart: Past, present, and the foreseeable future. Circulation Research, 91, 988-998.
22. Mann, D. L. (2011). The emerging role of innate immunity in the heart and vascular system: For whom the cell tolls. Circulation Research, 108, 1133-1145.
23. Manzano-Fernandez, S.; Mueller, T.; Pascual-Figal, D.; Truong, Q. A.; & Januzzi, J. L. (2011). Usefulness of soluble concentrations of interleukin family member ST2 as predictor of mortality in patients with acutely decompensated heart failure relative to left ventricular ejection fraction. The American Journal of Cardiology, 107, 259-267.
24. Matsubara, J.; Sugiyama, S.; Nozaki, T.; Sugamura, K.; Konishi, M.; Ohba, K.; et al. (2011). Pentraxin 3 is a new inflammatory marker correlated with left ventricular diastolic dysfunction and heart failure with normal ejection fraction. Journal of the American College of Cardiology, 57, 861-869.
25. Matsumoto, M.; Tsujino, T.; Lee-Kawabata, M.; Naito, Y.; Sakoda, T.; Ohyanagi, M.; et al. (2010). Serum interleukin-6 and C-reactive protein are markedly elevated in acute decompensated heart failure patients with left ventricular systolic dysfunction. Cytokine, 49, 264-268.
26. Mueller, C.; Laule-Kilian, K.; Christ, A.; Brunner-La Rocca, H. P.; & Perruchoud, A. P. (2006). Inflammation and long-term mortality in acute congestive heart failure. American Heart Journal, 151, 845-850.
27. Navarro-Gonzalez, J. F.; Mora, C.; Muros, M.; Jarque, A.; Herrera, H.; & Garcia, J. (2008). Association of tumor necrosis factor-alpha with early target organ damage in newly diagnosed patients with essential hypertension. Journal of Hypertension, 26, 2168-2175.
28. 2+ content in isolated failing and nonfailing human myocardium. Circulation Research, 85, 38-46.
29. Rauchhaus, M.; Doehner, W.; Francis, D. P.; Davos, C.; Kemp, M.; Liebenthal, C.; et al. (2000). Plasma cytokine parameters and mortality in patients with chronic heart failure. Circulation, 102, 3060-3067.
30. Rehman, S. U.; Mueller, T.; & Januzzi, J. L.; Jr. (2008). Characteristics of the novel interleukin family biomarker ST2 in patients with acute heart failure. Journal of the American College of Cardiology, 52, 1458-1465.
31. Reichlin, T.; Socrates, T.; Egli, P.; Potocki, M.; Breidthardt, T.; Arenja, N.; et al. (2010). Use of myeloperoxidase for risk stratification in acute heart failure. Clinical Chemistry, 56, 944-951.
32. Shah, R. V.; Chen-Tournoux, A. A.; Picard, M. H.; van Kimmenade, R. R.; & Januzzi, J. L. (2010). Galectin-3, cardiac structure and function, and long-term mortality in patients with acutely decompensated heart failure. European Journal of Heart Failure, 12, 826-832.
33. Subramanian, D.; Subramanian, V.; Deswal, A.; & Mann, D. (2011). New predictive models of heart failure mortality using time-series measurements and ensemble models. Circulation: Heart Failure, 4, 456-462.
34. Suzuki, S.; Takeishi, Y.; Niizeki, T.; Koyama, Y.; Kitahara, T.; Sasaki, T.; et al. (2008). Pentraxin 3, a new marker for vascular inflammation, predicts adverse clinical outcomes in patients with heart failure. American Heart Journal, 155, 75-81.
35. Torre-Amione, G.; Kapadia, S.; Benedict, C. R.; Oral, H.; Young, J. B.; & Mann, D. L. (1996). Proinflammatory cytokine levels in patients with depressed left ventricular ejection fraction: A report from the studies of left ventricular dysfunction (SOLVD). Journal of the American College of Cardiology, 27, 1201-1206.
36. Torre-Amione, G.; Kapadia, S.; Lee, J.; Bies, R. D.; Lebovitz, R.; & Mann, D. L. (1995). Expression and functional significance of tumor necrosis factor receptors in human myocardium. Circulation, 92, 1487-1493.
37. Tsutamoto, T.; Wada, A.; Ohnishi, M.; Tsutsui, T.; Ishii, C.; Ohno, K.; et al. (2004). Transcardiac increase in tumor necrosis factor-alpha and left ventricular end-diastolic volume in patients with dilated cardiomyopathy. European Journal of Heart Failure, 6, 173-180.
38. Ueland, T.; Aukrust, P.; Damas, J. K.; Gullestad, L.; & Yndestad, A. (2006). The tumor necrosis factor superfamily in heart failure. Future Cardiology, 2, 101-111.
39. van Kimmenade, R. R.; Januzzi, J. L.; Jr.; Ellinor, P. T.; Sharma, U. C.; Bakker, J. A.; Low, A. F.; et al. (2006). Utility of amino-terminal pro-brain natriuretic peptide, galectin-3, and apelin for the evaluation of patients with acute heart failure. Journal of the American College of Cardiology, 48, 1217-1224.
40. Vasan, R. S.; Sullivan, L. M.; Roubenoff, R.; Dinarello, C. A.; Harris, T.; Benjamin, E. J.; et al. (2003). Inflammatory markers and risk of heart failure in elderly subjects without prior myocardial infarction: The Framingham Heart Study. Circulation, 107, 1486-1491.
41. Villacorta, H.; Masetto, A. C.; & Mesquita, E. T. (2007). C-reactive protein: An inflammatory marker with prognostic value in patients with decompensated heart failure. Arquivos Brasileiros de Cardiologia, 88, 585-589.
42. Wang, T. J.; Wollert, K. C.; Larson, M. G.; Coglianese, E.; McCabe, E. L.; Cheng, S.; et al. (2012). Prognostic utility of novel biomarkers of cardiovascular stress: The Framingham Heart Study. Circulation, 126, 1596-1604.
43. Weinberg, E. O.; Shimpo, M.; Hurwitz, S.; Tominaga, S.; Rouleau, J. L.; & Lee, R. T. (2003). Identification of serum soluble ST2 receptor as a novel heart failure biomarker. Circulation, 107, 721-726.